High-performance liquid chromatography (HPLC) serves as the analytical benchmark for assessing the chemical purity, structural integrity, and degradation limits of synthetic PT-141. PX1 Research delivers fully documented, lot-specific HPLC chromatograms and mass spectrometry reports for every production batch to support reproducible laboratory research.
High-performance liquid chromatography (HPLC) serves as the analytical benchmark for assessing the chemical purity, structural integrity, and degradation limits of synthetic PT-141. PX1 Research delivers fully documented, lot-specific HPLC chromatograms and mass spectrometry reports for every production batch to support reproducible laboratory research.
PT-141 HPLC analysis utilizes reversed-phase high-performance liquid chromatography (RP-HPLC) to evaluate the purity, retention time, and structural integrity of the synthetic cyclic peptide PT-141 (Bremelanotide). By separating target peptides from truncated sequences or oxidized degradants based on hydrophobic interaction, RP-HPLC establishes quantifiable purity profiles—typically requiring ≥99% target peak area for rigorous in vitro and animal research.
When analyzing research-grade peptides, high-performance liquid chromatography ensures that impurities such as diastereomers, truncated sequences, or synthesis side-products are quantified prior to experimental use. Accurate quantification of peptide purity prevents confounding variables in receptor binding assays and cellular signaling studies.
PT-141, chemically designated as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, is a synthetic cyclic heptapeptide analog derived from alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, the central lactam bridge provides structural stability against enzymatic degradation, enhancing its bioactivity compared to linear peptides.
Primary research interest in PT-141 focuses on its function as a synthetic agonist across central melanocortin receptors, specifically demonstrating high binding affinity for the MC3R and MC4R receptor subtypes. Investigated for its role in central nervous system signaling pathways linked to sexual-health pathways and neuroendocrine responses, maintaining precise chemical sequence purity is essential for reliable affinity measurements across different melanocortin receptor agonists.
Reversed-phase HPLC separates target molecules based on hydrophobic interactions between the peptide analyte and a non-polar stationary phase (typically C18 silica columns). During analytical testing of PT-141, a binary mobile phase gradient consisting of Phase A (0.1% trifluoroacetic acid in purified water) and Phase B (0.1% trifluoroacetic acid in acetonitrile) is passed through the column at controlled flow rates.
As the organic modifier concentration increases, PT-141 elutes at a characteristic retention time. Spectrophotometric detection at 214 nm or 220 nm records absorbance, generating a chromatogram where the area under the curve (AUC) of the primary peak determines overall peptide purity percentage. Detailed methodologies regarding chromatographic verification can be reviewed in our technical brief on peptide purity HPLC analysis.
While RP-HPLC establishes chromatographic purity by resolving impurities based on retention time, it must be paired with Mass Spectrometry (MS) to verify molecular identity. Electrospray Ionization Mass Spectrometry (ESI-MS) measures the mass-to-charge ratio (m/z) of the eluted compound, confirming the exact molecular weight of PT-141 (1024.2 g/mol).
By evaluating doubly charged [M+2H]2+ and singly charged [M+H]+ ion peaks, analytical laboratories verify that the target primary peak corresponds precisely to the intact cyclic structure of Bremelanotide. This dual-verification protocol prevents misidentification caused by co-eluting impurities that share identical chromatographic retention times.
In preclinical literature, PT-141 is investigated for its capacity to bypass peripheral vascular mechanisms by acting directly on central melanocortin receptors within the hypothalamus. In vitro binding studies show potent activation of MC4R pathways, triggering downstream intracellular cyclic adenosine monophosphate (cAMP) accumulation.
Rodent and non-human primate research models utilize purified PT-141 to examine neural circuit activation involved in autonomic nervous system modulation and behavioral responses. Maintaining high HPLC-verified purity ensures that experimental observations stem solely from target receptor agonism rather than inflammatory responses induced by peptide contaminants or bacterial byproducts. Additional studies on melanocortin receptor dynamics can be found in the PX1 research library hub.
Evaluating melanocortin agonists requires comparing structural modifications and receptor selectivity profiles across related compounds. While PT-141 is a cyclic heptapeptide optimized for selective MC3R and MC4R signaling pathways without significant MC1R skin-pigmentation activation, its parent molecule Melanotan II displays non-selective agonism across MC1R, MC3R, MC4R, and MC5R. Additionally, targeted compounds such as Setmelanotide exhibit specific MC4R selectivity tailored for metabolic pathway research. Investigators seeking comprehensive melanocortin assay controls can compare these molecules within our all peptides catalog.
For analytical procedures and in vitro testing, lyophilized PT-141 acetate should be reconstituted using sterile deionized water or standard laboratory diluents such as bacteriostatic water. To protect the peptide's tertiary structure, gentle swirling should be employed until complete dissolution occurs; vigorous vortexing must be avoided to prevent mechanical shearing or aggregation.
Working solutions should be prepared under sterile laminar flow conditions using calibrated pipettes. For high-precision quantitative assays, stock solutions should be diluted directly into filtered mobile phase buffers immediately prior to HPLC column injection to ensure maximum signal baseline stability.
Lyophilized PT-141 displays excellent long-term stability when stored at -20°C or -80°C in a desiccated environment away from direct light exposure. Chemical degradation typically proceeds through thermal hydrolysis, deamidation of amino acid residues, or oxidation of the tryptophan residue present in the cyclic core.
Improper storage or repeated freeze-thaw cycles lead to degradation products visible on HPLC chromatograms as secondary peaks or peak broadening. Utilizing single-use experimental aliquots minimizes degradation risk and preserves chromatographic purity across multi-week assay schedules.
In addition to HPLC purity and MS identity, laboratory research compounds must be evaluated for bacterial endotoxins (lipopolysaccharides). High endotoxin concentrations can contaminate cell cultures, induce non-specific immune activation, and obscure receptor-mediated physiological data in animal models.
PX1 Research subjects every batch of PT-141 to chromogenic Limulus Amebocyte Lysate (LAL) testing, establishing strict endotoxin thresholds (<0.01 EU/μg). Manufactured in ISO 17025 accredited, GMP-compliant facilities in California and Arizona, every batch undergoes comprehensive quality testing documented on a downloadable Certificate of Analysis (COA). Facilities interested in volume sourcing can review our wholesale research accounts.
How does RP-HPLC determine the purity of PT-141?
Reversed-phase HPLC separates PT-141 from synthetic impurities and degradants based on hydrophobic interactions with a C18 column. Purity is calculated by integrating the area under the target peptide peak relative to total peak area detected at 214 nm or 220 nm.
What is the expected molecular weight of PT-141 on mass spectrometry reports?
The theoretical molecular weight of PT-141 (Bremelanotide acetate base) is 1024.2 g/mol. LC-MS analysis confirms this identity by observing target mass ions, such as [M+H]+ at ~1025.2 m/z and [M+2H]2+ at ~513.1 m/z.
How does PT-141 differ structurally from Melanotan II?
PT-141 is a metabolite derivative of Melanotan II featuring a modified hydroxyl group at the C-terminus. This structural refinement alters its receptor binding profile, reducing MC1R binding affinity while retaining central MC3R and MC4R activity.
Why is endotoxin testing critical for PT-141 used in laboratory research?
Endotoxins cause inflammatory responses, cytokine release, and cellular toxicity in vitro and in vivo. Quantitative LAL testing ensures that observed experimental results stem directly from melanocortin receptor agonism rather than bacterial contamination.
What solvent is recommended for reconstituting PT-141 for HPLC injection?
For HPLC mobile phase compatibility, lyophilized PT-141 is typically dissolved in sterile HPLC-grade water or a mixed solvent matching the initial mobile phase gradient (e.g., 95% H2O / 5% Acetonitrile with 0.1% TFA).
How should reconstituted PT-141 solutions be stored to prevent degradation?
Reconstituted liquid solutions should be stored at 2°C to 8°C for short-term analytical testing (up to 7 days) or aliquoted and frozen at -20°C to -80°C to prevent hydrolysis and oxidation.
Does PX1 Research provide lot-specific COAs for PT-141?
Yes. Every lot of PT-141 provided by PX1 Research includes a accessible, lot-specific Certificate of Analysis featuring full RP-HPLC chromatograms, mass spectrometry reports, and chromogenic endotoxin assay results.
Are PX1 Research compounds approved for human administration?
No. All compounds supplied by PX1 Research, including PT-141, are strictly intended for laboratory in vitro and preclinical research applications. They are not for human or veterinary consumption, therapy, or diagnostic procedures.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.